Dominic Tyer
SEPTEMBER 23, 2022
Moving from the ‘new normal’ to the ‘next normal’ and beyond, the landscape for pharma’s commercial operations continues to shift, with all stakeholders beginning to adjust to a post-pandemic world
European Pharmaceutical Review
SEPTEMBER 22, 2022
A breakthrough gene-editing therapy for human immunodeficiency virus type 1 (HIV) infection has entered first-in-human testing in what is being called “a major milestone in the search for a cure for HIV/AIDS”. EBT-101, a CRISPR-Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) has been administered to the first individual in a Phase I/II trial designed to establish its safety and efficacy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 22, 2022
It is the year 2030. You have just received the results from your whole genome sequencing test, offered through your public health provider, and discovered that you have a 75% chance of developing a rare form of cancer. But you are not panicking; your genomic data was automatically uploaded, with your permission, to your electronic health record (EHR), which is fully secured with blockchain technology.
MedCity News
SEPTEMBER 19, 2022
Much like a house of mirrors, responsibility for understanding and mitigating cyber risk in healthcare is difficult to distinguish and often depends on who you ask, especially when it comes to non-enterprise systems and devices.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Clarivate
SEPTEMBER 21, 2022
Clarivate draws on Web of Science publication and citation data to produce an annual list of Citation Laureates – researchers of Nobel class whose high-impact contributions have transformed their fields and changed our world for the better. Every October, the world watches as the Nobel Assembly votes to confer their prestigious prizes. While people around the globe can’t help but speculate about who will be chosen, Clarivate is the only organization to use quantitative data in addition to qualit
pharmaphorum
SEPTEMBER 20, 2022
Findings from the litifilimab trial, undertaken by Northwell Health’s Division of Rheumatology and The Feinstein Institutes for Medical Research, have been published in the New England Journal of Medicine and show promise for those who have been diagnosed with systemic lupus erythematosus (SLE). Sponsored by Biogen Inc., data from the phase 2 LILAC (Part A) clinical trial published this month shows that the experimental lupus therapy could reduce disease activity in the joints of patients, globa
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 22, 2022
These are the three changes health-tech needs to make to recreate Amazon, Uber or Venmo-like experiences in healthcare that will most accurately help to digitally replicate the humanized interactions that patients want:
Medgadget
SEPTEMBER 23, 2022
Scientists at Shanghai Tongji University in China have created a face mask that can alert the wearer to the presence of respiratory viruses in the surrounding environment, including the viruses behind COVID-19 and influenza. The mask includes aptamers, which are short sequences of DNA or RNA that can bind to protein targets. When viral particles bind to the aptamers, ion-gated transistors boost the signal so that the mask can sensitively detect small amounts of virus.
pharmaphorum
SEPTEMBER 21, 2022
The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. Tezspire (tezepelumab) has been cleared for use in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal produ
Pharmaceutical Technology
SEPTEMBER 19, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AstraZeneca ’s Evusheld (formerly AZD7442) for Covid-19 in the European Union (EU). This therapy is intended to treat adult and adolescent Covid-19 patients aged 12 years and above, who do not need additional oxygen and are at greater disease progression risk.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
SEPTEMBER 22, 2022
A Biogen drug designed for a genetically defined form of amyotrophic lateral sclerosis led to patient improvement at a 12- month analysis, according to data now published in the New England Journal of Medicine. Biogen had already filed an application seeking FDA approval of the ALS drug, tofersen; a regulatory decision is expected by January.
European Pharmaceutical Review
SEPTEMBER 22, 2022
At Climate Week NYC GSK presented its new Sustainable Procurement Programme, announcing a fresh agenda, outlining how they will support their suppliers to succeed in their bold environmental objectives: have a net zero climate impact and a net positive impact on nature. This is an important move, as many GSK suppliers do not have easy geographical access to green infrastructure or green financing.
Healthcare Success
SEPTEMBER 20, 2022
Help Providers Win New Patients from Large Local Businesses with These Tactics. Large or dominant employers in your local communities are excellent targets of opportunity for new patients and cases. Most healthcare providers have local businesses that are (or could be) a source of new business. Whether it’s a company that's conveniently located across the street, or a dominant employer in the community, your providers want their business—here’s how you can help them win it.
PM360
SEPTEMBER 23, 2022
NEW YORK, NY, September 23, 2022: PM360 , a leading life sciences marketing industry trade publication, announced the winners of their 14 th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022. The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries.
MedCity News
SEPTEMBER 17, 2022
As the U.S. healthcare industry continues to advance value-based care and population health, lab testing price transparency and payment integrity programs should be a priority.
European Pharmaceutical Review
SEPTEMBER 20, 2022
In a recent paper, researchers demonstrated the comparability of a green high performance liquid chromatography (HPLC) for the determination and screening of typical antipsychotic drugs both in bulk and pharmaceutical formulation. Antipsychotics are used to treat a variety of serious mental disorders including schizophrenia and bipolar disorder, in which manic states may require management with multiple drugs.
Copyright Clearance Center
SEPTEMBER 22, 2022
As with my earlier post in this series on the overall role of peer review in the scholarly and scientific publishing process, for Peer Review Week 2022 we are reposting our pieces in this series. And little bit of updated information on the topics we covered: * Psychology, in particular, seems to have a replicability problem ; even outside of psych, everyone knows that bad papers are still getting published (and they may even have a discoverability advantage ). * Retraction Watch is still engage
Pharmaceutical Technology
SEPTEMBER 19, 2022
The US Food and Drug Administration (FDA) has awarded Accelerated Approval for bluebird bio ’s Skysona (elivaldogene autotemcel; eli-cel) for slowing neurologic dysfunction progression in early, active cerebral adrenoleukodystrophy (CALD) patients. The treatment is indicated for usage in boys aged four to 17 years with CALD. Through certain Qualified Treatment Centers in the country, Skysona is anticipated to be made available commercially by the end of this year.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
SEPTEMBER 23, 2022
Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure. CEO Allen Cunningham said the new cash comes on the heels of results from a mid-stage obesity study treatment with the Rivus drug led to fat loss while also preserving skeletal muscle.
European Pharmaceutical Review
SEPTEMBER 21, 2022
In its first meeting since July, the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommended these 12 medicines for approval: Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season (when there is a risk of RSV infection in the community).
PharmaTech
SEPTEMBER 20, 2022
Experts from Umoja Biopharma dive into cell therapy development in this episode of the Drug Solutions Podcast, including the greatest advancements in cell therapy to date, areas for improvement, the biggest trends in cell therapy development, and retention as a pain point.
PharmExec
SEPTEMBER 20, 2022
Rohit Gupta is vice president of analytics strategy and transformation at Beghou Consulting - he works with biopharma leaders on all facets of drug commercialization, from market sizing strategies, to launch planning, to business analytics.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
SEPTEMBER 23, 2022
Cheryl Larson, president and CEO of Midwest Business Group on Health, said employers are worried that the consolidation of healthcare companies will lead to higher costs for employers and patients. She made her comments following McKesson’s announcement that it has agreed to acquire Rx Savings Solutions, but declined to speak specifically about the deal.
European Pharmaceutical Review
SEPTEMBER 20, 2022
The Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have announced that biosimilar medicines authorised in the European Union (EU) can now be interchanged with their reference medicine or an equivalent biosimilar product. Interchanging biosimilars is an acceptable practise already used by many Member States. However, the current lack of certainty whether interchangeability is acceptable EU-wide has prompted this decision.
Pharmaceutical Technology
SEPTEMBER 23, 2022
Rivus Pharmaceuticals has raised $132m in a Series B funding round to clinically advance its lead candidate, HU6, for the treatment of obesity and cardio-metabolic disorders. RA Capital Management led the financing round, which also saw participation from Bain Capital Life Sciences and BB Biotech. Existing investors of the company, including Longitude Capital, Medicxi and RxCapital, also took part in the round.
pharmaphorum
SEPTEMBER 22, 2022
BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM) – a rare form of non-Hodgkin lymphoma (NHL). The final appraisal document from health technology assessment (HTA) agency NICE says that Brukinsa can be used to treat WM in adults who have had at least one prior treatment, and only if bendamustine plus rituximab therapy is also suitable.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
MedCity News
SEPTEMBER 20, 2022
Employers expect healthcare costs to increase 6% next year, up from the 5% increase they are experiencing this year. Respondents don’t see this improving down the road either, with 71% saying they anticipate moderate to significant increases over the next three years.
European Pharmaceutical Review
SEPTEMBER 20, 2022
New data supports the potential use of Biogen’s and Sage Therapeutics’ zuranolone as a potential episodic treatment for people with major depressive disorder (MDD). Zuranolone is an investigational oral 14-day treatment under clinical development for adult patients with MDD and postpartum depression. In the ongoing open-label, longitudinal SHORELINE Study in MDD, the median time to the first repeat treatment course for those patients who responded to the initial 14-day treatment course was
Medgadget
SEPTEMBER 20, 2022
At the University of Minnesota a team of researchers has developed a 3D printed light sensing wearable that can help people with light-sensitive diseases, such as lupus, to understand more about the types of light that can exacerbate their symptoms. Many people with lupus are sensitive to light, such as sunlight or even regular indoor light, but they may not know what specific light conditions are likely to cause flare-ups.
PharmExec
SEPTEMBER 21, 2022
A cookieless future is on the horizon, so marketers across all industries are being forced to rethink their strategies and plan for the future. What does that entail?
Expert insights. Personalized for you.
130 
Let's personalize your content